Gaelle-Christie Haddad, Anthony El Dada, Sergio Sbeih, Tony Kazzi, Karam Karam, Louis A Chaptini
{"title":"Ulcerative colitis and bullous pemphigoid: Direct association or a medication side effect: A case report.","authors":"Gaelle-Christie Haddad, Anthony El Dada, Sergio Sbeih, Tony Kazzi, Karam Karam, Louis A Chaptini","doi":"10.12998/wjcc.v13.i9.101363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. It is associated with other autoimmune disorders and the use of certain drugs. We describe a case of BP in a patient with ulcerative colitis (UC) treated with mesalamine.</p><p><strong>Case summary: </strong>A 38-year-old male patient with UC and a history of multiple flares was maintained on mesalamine with good clinical response. One year after starting mesalamine, he sought medical care following the onset of a severe itchy rash of several weeks' duration with a recent appearance of skin bullae. A biopsy of the skin revealed subepidermal blistering dermatitis with focal eosinophilic spongiosis. Direct immunofluorescence studies revealed linear IgG and C3 immune reactant deposits at the dermoepidermal junction, consistent with the diagnosis of BP. Prednisone therapy alleviated his symptoms. However, tapering prednisone led to re-eruption of the bullae.</p><p><strong>Conclusion: </strong>BP should be considered when patients with UC develop skin manifestations. Although BP is not one of the extraintestinal manifestations of UC, there may be an association between these two conditions. Whether treatment with mesalamine or other therapeutic agents plays a role in the development of BP remains unclear.</p>","PeriodicalId":23912,"journal":{"name":"World Journal of Clinical Cases","volume":"13 9","pages":"101363"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670022/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical Cases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12998/wjcc.v13.i9.101363","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. It is associated with other autoimmune disorders and the use of certain drugs. We describe a case of BP in a patient with ulcerative colitis (UC) treated with mesalamine.
Case summary: A 38-year-old male patient with UC and a history of multiple flares was maintained on mesalamine with good clinical response. One year after starting mesalamine, he sought medical care following the onset of a severe itchy rash of several weeks' duration with a recent appearance of skin bullae. A biopsy of the skin revealed subepidermal blistering dermatitis with focal eosinophilic spongiosis. Direct immunofluorescence studies revealed linear IgG and C3 immune reactant deposits at the dermoepidermal junction, consistent with the diagnosis of BP. Prednisone therapy alleviated his symptoms. However, tapering prednisone led to re-eruption of the bullae.
Conclusion: BP should be considered when patients with UC develop skin manifestations. Although BP is not one of the extraintestinal manifestations of UC, there may be an association between these two conditions. Whether treatment with mesalamine or other therapeutic agents plays a role in the development of BP remains unclear.
期刊介绍:
The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.